Neurocognitive Impairment in Patients with HIV and Depression in Nigeria

References (43)

1. 1 The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
2. 2 The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI [DOI]
3. 3 HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy [DOI]
4. 4 Cognitive impairment in depression: a systematic review and meta-analysis [DOI]
5. 5 TROPICAL MEDICINE & INTERNATIONAL HEALTH [DOI]
6. 6 COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS [DOI]
7. 7 A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder [DOI]
8. 8 Cognitive dysfunction in HIV patients despite long-standing suppression of viremia [DOI]
9. 9 Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline [DOI]
10. 10 Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort [DOI]
11. 11 Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semi-urban Entebbe district, Uganda [DOI]
12. 12 Does highly active antiretroviral therapy improve neurocognitive function? A systematic review [DOI]
13. 13 Psychosocial Factors Affecting Medication Adherence Among HIV-1 Infected Adults Receiving Combination Antiretroviral Therapy (cART) in Botswana [DOI]
14. 14 Neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa: a systematic review and meta-analysis [DOI]
15. 15 Sex differences in HIV-associated cognitive impairment [DOI]
16. 16 Population normative data for the 10/66 Dementia Research Group cognitive test battery from Latin America, India and China: a cross-sectional survey [DOI]
17. 17 The Stick Design test: A new measure of visuoconstructional ability [DOI]
18. 18 Depression Among HIV/AIDS Patients on Highly Active Antiretroviral Therapy in the Southwest Regional Hospitals of Cameroon: A Cross-Sectional Study [DOI]
19. 19 Prevalence of HIV-Associated Neurocognitive Disorder (HAND) among Patients Attending a Tertiary Health Facility in Northern Nigeria [DOI]
20. 20 Depression Among HIV-Positive Individuals in Botswana: A Behavioral Surveillance [DOI]
21. 21 Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda [DOI]
22. 22 Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia [DOI]
23. 23 Neurobehavioral Effects in HIV-Positive Individuals Receiving Highly Active Antiretroviral Therapy (HAART) in Gaborone, Botswana [DOI]
24. 24 Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria [DOI]
25. 25 Depression and diagnosis of neurocognitive impairment in HIV-positive patients [DOI]
26. 26 Psychological complications associated with HIV/AIDS infection among children in South-South Nigeria, sub-Saharan Africa [DOI]
27. 27 Neuropathogenesis of human immunodeficiency virus infection [DOI]
28. 28 Cognitive reserve and neuropsychological functioning in older HIV-infected people [DOI]
29. 29 Neurocognitive impairment associated with predominantly early stage HIV infection in Abuja, Nigeria [DOI]
30. 30 The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults [DOI]
31. 31 The Stick Design Test on the assessment of older adults with low formal education: evidences of construct, criterion-related and ecological validity [DOI]
32. 32 Depression and Suicide Risk among HIV Positive Individuals Attending an Out Patient HIV/Aids Clinic of a Nigerian Tertiary Health Institution [DOI]
33. 33 Symptoms of depression and rates of neurocognitive impairment in HIV positive patients in Beijing, China [DOI]
34. 34 A Normative Study of the Color Trails Test in the Greek Population [DOI]
35. 35 An Overview of the Biological and Psychosocial Context Surrounding Neurocognition in HIV [DOI]
36. 36 HIV-related neurocognitive impairment screening: the patient's perspective on its utility and psychological impact [DOI]
37. 37 Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort [DOI]
38. 38 [CERAD (The Consortium to Establish a Registry for Alzheimer's Disease) criteria].
39. 39 Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda [DOI]
40. 40 Problems screening for HAND among the educationally disadvantaged [DOI]
41. 41 Factors affecting adherence to antiretroviral treatment among patients living with HIV/AIDS, in Bale zone, south eastern Ethiopia [DOI]
42. 42 Impact of Symptomatic HIV- Related Neurocognitive Disorders in Survival of HIV- Infected Individuals: A Systematic Review and Meta-Analyses [DOI]
43. 43 Sample Size Determination [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• First Trimester Fasting Blood Glucose as a Screening Tool for Diabetes Mellitus in a Teaching Hospital Setting in Nigeria — shares topic coverage
• The Nature and Complications of Acute Traumatic Cervical Spinal Cord Injury in a University Hospital in Nigeria — shares topic coverage
• Musculoskeletal Complications of Sickle Cell Anaemia and Their Management Approaches in Makurdi, Nigeria — shares topic coverage
• Work-related Musculoskeletal Disorders among Radiologists in Nigeria — shares topic coverage
• The Skills of Cardiopulmonary Resuscitation in Some Professional and Student Teachers Compared — shares topic coverage